Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Antioxidant gel preserves islet function after pancreas removal June 7, 2024 Personalization key to patient satisfaction with AI doctors November 1, 2024 Oropouche virus spreads in South America as scientists warn of potential outbreaks in the U.S. October 3, 2024
Oropouche virus spreads in South America as scientists warn of potential outbreaks in the U.S. October 3, 2024